Health Canada issued a Notice of Compliance with Conditions for LEQEMBI (lecanemab), authorizing Eisai and Biogen’s monoclonal antibody for adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease who are ApoE ε4 non‑carriers or heterozygotes and who have confirmed amyloid pathology. The approval marks another national authorization for lecanemab, which the companies say is the first treatment shown to slow cognitive and functional decline by targeting soluble aggregated amyloid‑beta. Eisai and Biogen said they will work with stakeholders to support timely patient access and diagnostics for early disease identification. Eisai emphasized its multi‑decade Alzheimer’s research investment in statements accompanying the regulatory notice.